Lawrence N. Shulman, M.D.
Associate Professor, Department of Medicine, Harvard Medical School
Physician, Adult Oncology, Brigham And Women's Hospital
Contact Info
Lawrence Shulman
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Dana 1608
Phone: 617-632-2277
Fax: 617-632-2260
Email not available
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-2277
Edna_Senato@dfci.harvard.edu
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Dana 1608
Phone: 617-632-2277
Fax: 617-632-2260
Email not available
Assistant
Edna SenatoDana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-2277
Edna_Senato@dfci.harvard.edu
DF/HCC Program Affiliation
Lymphoma and MyelomaTranslational Pharmacology and Early Therapeutic Trials
Research Abstract
Research is centered around new therapeutics for both patients with breast cancer and patients with malignant lymphomas. This includes the use of new agents and combining chemotherapeutic agents with radiation therapy. In addition, research is directed towards the development of new investigational agents as part of the Phase I experimental therapeutics program.Publications
- Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN.Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.Int J Radiat Oncol Biol Phys 1999 M
10760430 - Dubey A, Recht A, Come SE, Gelman RS, Silver B, Harris JR, Shulman LN.Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study.Int J Radiat Oncol Biol Phys 1999 Nov 1;45(4):877-84.
10571193
